CORUM Group Limited has confirmed it expects to recognise a "non-cash net impairment charge for goodwill" of approximately $6.3 million in its full year accounts which will be released this week.
The figure reflects Corum's expectation that the upcoming launch of its new Corum Clear suite of products will, over time, "impact the returns of the legacy products to which goodwill relates".
The company said the Corum Clear project is now well advanced, with market response to early prototypes "extremely positive".
"The Corum Clear product suite is designed to be best of breed, encompassing a contemporary new dispense system, leading-edge cloud reporting platfrom, update Point of Sale and head office store management tools," Corum said.
The impairment is a non-cash item with no impact on EBITDA.
The above article was sent to subscribers in Pharmacy Daily's issue from 28 Aug 17
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 28 Aug 17
